PDE IV inhibitors

Details PDE IV inhibitors PDE IV inhibitors

2006-10-03

2006-10-03

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S113000

Reexamination Certificate

active

07115623

ABSTRACT:
The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1):wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

REFERENCES:
patent: 4452800 (1984-06-01), Sherlock
patent: 4786642 (1988-11-01), Teulon
patent: 5817670 (1998-10-01), Takayama et al.
patent: 6642250 (2003-11-01), Aotsuka et al.
patent: 62-228076 (1987-06-01), None
patent: 96/06843 (1996-07-01), None
patent: 01/42244 (2001-06-01), None
STN pp. (7).

Affiliated with

Also associated with

Rating

PDE IV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PDE IV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDE IV inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3666318